HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

In vitro validation of a Respimat® adapter for delivery of inhaled bronchodilators during mechanical ventilation.

AbstractBACKGROUND:
Inhaled bronchodilators are frequently used in patients with chronic obstructive pulmonary disease (COPD). However, there has been no efficient way to administer the long-acting anticholinergic tiotropium to mechanically ventilated patients. The aim of this in vitro study was to compare the fine particle dose (FPD) output of a specifically designed adapter with other accessory devices for the delivery of bronchodilators using the Respimat® (RMT) inhaler by simulating the specific inhalation flow profiles of patients with COPD.
METHODS:
Using characteristic flow profiles from COPD patients being weaned off mechanical ventilation, an in vitro study was performed analyzing the FPD achieved with different accessory devices (connectors, spacers, AeroTrachPlus valved holding chamber), which can be used to deliver drugs from pressurized metered dose inhalers (pMDI) and RMT inhalers to artificial airways. Fenoterol pMDI, tiotropium RMT, and a fixed-dose combination of salbutamol and ipratropium delivered by pMDI or RMT, were used as bronchodilators. Aerosols were collected by a next-generation impactor.
RESULTS:
The RMT inhaler, combined with a new in-line adapter, was superior to other inhaler device connector or spacer combinations in FPD delivery during simulated mechanical ventilation (p<0.01). The outcome with the RMT inhaler/RMT adapter combination during simulation of mechanical ventilation was comparable to the measurements with the RMT/AeroTrachPlus valved holding chamber during simulation of spontaneous breathing. The delivery rates of the RMT adapter were not significantly affected by the administered bronchodilators or by the type of artificial airway (endotracheal or tracheostomy tube) employed.
CONCLUSIONS:
The RMT inhaler combined with the prototype in-line adapter was better than the other accessory device combinations in fine particle deposition of inhaled bronchodilators during mechanical ventilation. Further research is required to determine the clinical relevance of these in vitro findings.
AuthorsDominic Dellweg, Herbert Wachtel, Ekkehard Höhn, Michael P Pieper, Thomas Barchfeld, Dieter Köhler, Thomas Glaab
JournalJournal of aerosol medicine and pulmonary drug delivery (J Aerosol Med Pulm Drug Deliv) Vol. 24 Issue 6 Pg. 285-92 (Dec 2011) ISSN: 1941-2703 [Electronic] United States
PMID21870959 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Validation Study)
Chemical References
  • Aerosols
  • Bronchodilator Agents
Topics
  • Aerosols
  • Bronchodilator Agents (administration & dosage)
  • Humans
  • Nebulizers and Vaporizers
  • Pulmonary Disease, Chronic Obstructive (drug therapy)
  • Respiration, Artificial

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: